冯 蕾,吕兴茹,王 原,刘 伟,等.二甲双胍治疗乳腺癌分子机制及临床应用研究进展[J].,2018,5(9):43-47.
二甲双胍治疗乳腺癌分子机制及临床应用研究进展
The progress of metformin in the molecular mechanism of breast cancer treatment and clinical application
投稿时间:2018-04-05  最后修改时间:2018-05-07
DOI:10.12095/j.issn.2095-6894.2018.09.009
中文关键词:  二甲双胍;乳腺癌; 微小RNA ;多重耐药性;肿瘤干细胞
英文关键词:Metformin; Breast cancer; MicroRNA; Multiple drug resistant; Cancer stem cells
基金项目:
作者单位E-mail
冯 蕾 河北医科大学第四医院 1832059681@qq.com 
吕兴茹 河北医科大学  
王 原 河北医科大学第四医院  
刘 伟 河北医科大学  
摘要点击次数: 55
全文下载次数: 86
中文摘要:
      【摘 要】糖尿病是乳腺癌发病的高危因素,并影响乳腺癌患者的预后。二甲双胍是糖尿病一线用药,越来越多的证据表明,其   还能通过多种途径起到抗肿瘤作用。近年来,许多学者提出了二甲双胍在抑制乳腺肿瘤干细胞及逆转乳腺癌细胞耐药性等方面   的新思路。此外,有学者新开发出一种药物工具来控制二甲双胍的释放。本文将对二甲双胍治疗乳腺癌分子细胞机制及临床应   用研究进展进行阐述。
英文摘要:
      【Abstract】Diabetes is a high risk factor for breast cancer and affects the prognosis of breast cancer patients. The increasing evidence   indicates that metformin, a first?line oral hypoglycemic drug for the treatment of type 2 diabetes, has anti?tumor effects in a variety of   pathways. In recent years, many studies have put forward metformin ??s role in inhibiting breast cancer stem cells and resensitizing multiple   drug resistant breast cancer cell lines. Besides, a study has developed a pharmacological tool to control the release of metformin. In this   review, we aim to describe the new molecular cell mechanism of metformin in the treatment of breast cancer and the progress of clinical   application.
查看全文  查看/发表评论  下载PDF阅读器
关闭